Rare Kidney Stone Consortium Biobank

Recruiting now

Conditions studied: Primary Hyperoxaluria, Dent Disease, APRT Deficiency, Cystinuria

In brief

This study is being done to obtain samples from patients with primary hyperoxaluria, cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent disease, and from their family members, for use in future research.

Key facts

Study ID

NCT02026388

Run by

Mayo Clinic

People needed

2000

Starts

2013-05-01

Expected to finish

2030-06-01

Last updated by the study team

2026-07-22

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of primary hyperoxaluria (PH) meeting one or more of the following criteria:
• Liver biopsy documenting alanine-glyoxylate aminotransferase (AGT) activity below the normal reference range confirming PH type 1 OR Liver biopsy documenting glyoxylate reductase/hydroxypyruvate reductase (GR/HPR) activity below the normal reference range confirming PH type 2
• Molecular genetic analysis (DNA testing) confirming mutations known to cause PH type 1, PH type 2, or PH type 3
• Urinary oxalate excretion of greater than 0.8 mmol/1.73 m2/day (>70 mg/1.73 m2/day) in the absence of a identifiable causes of secondary hyperoxaluria, including gastrointestinal disease known to cause enteric hyperoxaluria
• A patient in end stage kidney failure, in whom neither a liver biopsy nor mutational analysis are available must have: (a) A plasma oxalate concentration of greater than 60 umol/L and a kidney biopsy confirming extensive oxalate deposits OR (b) Evidence of systemic oxalosis
• Participants in the previous protocol "Tissue Bank of Urine, Blood, and Tissue Samples Collected from the Patients with Primary Hyperoxaluria" 'Mayo IRB #' #80-04. They have already consented to bank their samples and that consent will serve to enroll them in this study.
• Diagnosis of Dent disease meeting one or more of the following criteria:
• Identified mutation of the gene that encodes for chloride exchange transporter 5 (CLCN5)
• Low molecular weight proteinuria and hypercalciuria
• Low molecular weight proteinuria and nephrocalcinosis
• Diagnosis of APRT disease meeting one or more of the following criteria:
• Suspected dihydroxyadeninuria and absent APRT enzyme activity measured in red blood cells (RBCs).
• Homozygosity, or compound heterozygosity, for known disease-causing APRT mutations.
• Passage of dihydroxyadenine stones (confirmed with stone analysis).
• Diagnosis of Cystinuria meeting one or more of the following criteria:
• Stone analysis demonstrating that the stone contains cystine
• Increased urinary cystine excretion (>250 mg/gm creatinine)
• Relative of someone with confirmed primary hyperoxaluria, Dent disease, APRT deficiency (also known as dihydroxyadeninuria), or cystinuria

You may not qualify if…

• Stone formers who do not meet the inclusion criteria for primary hyperoxaluria, cystinuria, Dent disease, or APRT deficiency.
• Unwilling or unable to provide consent/assent.

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.